The closing price of Pacific Biosciences of California Inc (NASDAQ: PACB) was $4.88 for the day, down -5.97% from the previous closing price of $5.19. In other words, the price has decreased by -$0.3100 from its previous closing price. On the day, 7636150 shares were traded. PACB stock price reached its highest trading level at $5.2300 during the session, while it also had its lowest trading level at $4.7000.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of PACB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.81. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 when HENRY CHRISTIAN O sold 1,979 shares for $5.26 per share. The transaction valued at 10,412 led to the insider holds 1,005,078 shares of the business.
Kim Susan G. sold 831 shares of PACB for $4,372 on Feb 20. The insider now owns 282,758 shares after completing the transaction at $5.26 per share. On Feb 16, another insider, HENRY CHRISTIAN O, who serves as the insider of the company, sold 79,038 shares for $5.96 each. As a result, the insider received 470,908 and left with 1,007,057 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 1.39B and an Enterprise Value of 1.69B. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.52 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 8.43 whereas that against EBITDA is -6.10.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $4.97. The 50-Day Moving Average of the stock is 7.2314, while the 200-Day Moving Average is calculated to be 9.6566.
Shares Statistics:
PACB traded an average of 7.81M shares per day over the past three months and 9.06M shares per day over the past ten days. A total of 267.74M shares are outstanding, with a floating share count of 252.04M. Insiders hold about 5.94% of the company’s shares, while institutions hold 98.51% stake in the company. Shares short for PACB as of Feb 15, 2024 were 40.38M with a Short Ratio of 5.17, compared to 36M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.10% and a Short% of Float of 16.74%.
Earnings Estimates
The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.3, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.93 and -$1.1 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.85, with 13 analysts recommending between -$0.68 and -$1.1.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $52.76M to a low estimate of $48M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $34.38M, an estimated increase of 46.20% from the year-ago figure.
A total of 14 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $244.7M, while the lowest revenue estimate was $229.5M, resulting in an average revenue estimate of $239.02M. In the same quarter a year ago, actual revenue was $200.52M, up 19.20% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $350.1M in the next fiscal year. The high estimate is $395M and the low estimate is $299M. The average revenue growth estimate for next year is up 46.50% from the average revenue estimate for this year.
